Friday, September 18, 2009

Tv Center Pro Windows 7

TAMSULOSIN CEUTA: NEW PERSPECTIVES GENE THERAPY IN THE EYES OF OPHTHALMOLOGY











A recent study by researchers at the University of Washigto n has been estaurar color vision in adult monkeys with impaired perception of red and green.
x
The study was published in the journal "Nature" ("Colour blindness corrected by gene therapy"), and its makers claim that the treatment could work in humans, says Jay Neitz, leader of the team.
x
The study represents a significant advance, since until now the scientific community does not think it was adult brain can be manipulated to correct color blindness. Thus, it is considered only during the first years of life, when there is greater "plasticity" cerebral, it was possible to add new sensory information to people, which may improve vision.
x
Neitz teacher team managed to introduce therapeutic genes into cells in the retina of the eye of an adult male monkey, containing the DNA code needed for cells could distinguish between red and green.
x
therapy seems to have been a success, since the treated monkeys were able to pass tests of color, being able to correctly identify the red forms that appeared in green funds.
x
Animals received treatment for two years, scientists have managed to keep its vision corrected from those tests.
x
Still to assess what might be the long-term effects of treatment.
x
As explained by Dr Winfried Amoaku, an expert in ophthalmology at the University of Nottingham UK (United Kingdom), speaking to the BBCA, said the research could benefit approximately 7% of men and 1% de las Mujeres born with vision problems.
x
basic information and guidance. For a personalized information see su ophthalmologist.
x
OJOS of Ceuta. Innovating in Ophthalmology.
Ophthalmological Center DR. Medina Catoira

Wednesday, September 16, 2009

Denise Milani akiba-online

DALTON CEUTA: PRECAUTIONS IN CATARACT SURGERY IN PATIENTS with tamsulosin

www.qxeyes.com













A retrospective study published in the Journal of the American Medical Association shows the association between the use of tamsulosin , a drug commonly used in the treatment of benign prostatic hypertrophy , and the presence of serious complications during and extraoperatorias during cataract surgery.
X
The study shows that patients who receive or have received recent treatment with tamsulosin in the 14 days prior to surgery have a significantly higher incidence of complications in surgery cataract, increased incidence that it has been observed with other alpha-blockers used in the treatment of benign prostatic hypertrophy (BPH) .
X
Tamsulosin is a drug blocking alpha-adrenergic receptor that is frequently prescribed for the treatment of prostatic hypertrophy. Given its frequent use, patients should be warned of the perioperative risks and the ophthalmologist must be prepared for possible complications, since the suspension of treatment before surgery so does not reduce the risk of complications such as intraoperative floppy iris syndrome (IFIS).
x
To reduce potential intraoperative complications (IFIS, capsular rupture, vitreous loss, retinal detachment, ..) have proposed pharmacologic strategies and instruments such as the use of cycloplegic powerful (atropine, homatropine), denser viscoelastic under fluid flow, iris retractors, pupil dilator rings and expanders.
x
Both the patient and the ophthalmologist should be aware, be advisable for the surgeon to warn the patient before surgery if you are undergoing treatment with Tamsulosin for prostatic hypertrophy (Omnic, Omnic Geese, Urolosin, Urolosin geese) .
x
JAMA. 2009; 301:1991-1996, 2044-2045.
x
Basic Information and indicative. For personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes

Wednesday, September 9, 2009

Gay Saunas In Gloucester

CEUTA OPHTHALMOLOGY EYE: THE VITAMIN B6, B12 and Folic Acid CAN REDUCE THE RISK OF MACULAR DEGENERATION ASSOCIATED WITH AGE IN WOMEN

















A study published in the journal Archives of Internal Medicine seems to show that the daily diet supplemented with Folic Acid, Pyridoxine and Cyanocobalamin seems reduce the risk of macular degeneration associated with age in women with cardiovascular disease risk.

Epidemiological studies indicate an association between elevated levels homocysteine \u200b\u200b blood and the risk of wet AMD , so researchers Brigham and Women's Hospital, Harvard Medical School in Boston, Massachusetts, and colleagues from the Women's Antioxidant and Folic Acid Cardiovascular Study have examined results of the incidence of wet AMD in women with elevated homocysteine \u200b\u200blevels which has been treated combined with folic acid, pyridoxine (B6) and cyanocobalamin (B12) , compared with placebo. The average duration of follow up was 7.3 years.

finally The results showed a lower incidence of wet AMD in the treated group, statistically significant, reducing the risk of it.

Since there are currently no meansof prevent AMD in the initial stages, except the strict smoking ban, these results become important clinically and should be confirmed in other populations of men and women.

Arch Intern Med. 2009, 169:335-341.

Basic information and guidance. For personalized information consult your ophthalmologist.

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN


Wednesday, September 2, 2009

Laser Anniversary Joke

CEUTA OPHTHALMOLOGY EYE TREATMENT WITH LOW DOSES OF retinal vein occlusion fibrinolytic

retinapanama.com











A recent study in Retina (July / August 2009 - vol 29 - 932-940 ps) seems to indicate the improvement in outcome in patients with retinal vein occlusion treated with low doses of fibrinolytics compared to those treated with hemodilution.
x
The RESEARCHERS s ( Hattenbach, Lars-Olof MD; FRIEDRICH ARNDT, CARL MD; Lerche, RALF MD; Scharrer, INGE MD; Baatz, Holger MD, margin, FABRICE MD; Richard, Gisbert MD; BEHRENS- BAUMANN, WOLFGANG MD; OHRLOFF, CHRISTIAN MD ) Ometer s randomly 53 patients with occlusion of the central retinal vein (CRVO) or occlusion of branch retinal vein (BRVO ) to treatment with intravenous thrombolysis with 50 mg of recombinant tissue plasminogen activator (rt-PA) or hemodilution within the 11 days of onset of symptoms.
x
All patients were followed up one year.
x
Among patients with CRVO half BCVA was 20/60 in the rt-PA group compared to a BCVA of 20/400 in the hemodilution group.
x
Among patients with BRVO, there was a trend toward improved vision in rt-PA group differences did not reach statistical significance, probably due to the small number of patients group.
x
Basic information and guidance. For personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN